Empirical dosimetric characterization of model I125-SL 125iodine brachytherapy source in phantom
- PMID: 11190963
- DOI: 10.1118/1.1323980
Empirical dosimetric characterization of model I125-SL 125iodine brachytherapy source in phantom
Abstract
Low-energy photon emitting radionuclides encapsulated for a permanent implant are routinely applied in prostate cancer brachytherapy. Before clinical use, a new source design requires full dosimetric analysis and calibration standardization. The results of one such experimental measurement and analysis are reported here for a new design of 125I source, model I125-SL. Dose measurements were made using standard methods employing thermoluminscent dosimeters in a water equivalent plastic phantom, in accord with the AAPM Task Group #43 recommendation of liquid water reference material. Precision machined bores in the phantom located dosimeters and source(s) in a reproducible fixed geometry providing for transverse-axis and angular dose profiles over a range of distances from 0.17 to 10 cm. The data were analyzed in terms of parameters recommended by AAPM TG43. The dose-rate constant, lambda, was evaluated by two methods, the first with reference to a 60Cobalt standard, accounting for response variation with photon energy spectrum. Second, the dose-rate constant was determined with reference to phantom measurements using NIST traceable calibrated model 6702 and 6711 sources. The radial dose function, g(r), the anisotropy function, F(r,theta), the anisotropy factor, phi(an)(r), and the point-source approximation anisotropy constant, phi(an), were derived from one- and two-dimensional dose distribution data measured in the phantom, accounting for finite dosimeter volume and with attention to interchip effects. The results are compared to TG43 and other existing data for 125I sources. The new source is comparable to the model 6711 source design.
Similar articles
-
Dosimetric characterization of a new design 103 palladium brachytherapy source.Med Phys. 1999 Nov;26(11):2465-70. doi: 10.1118/1.598765. Med Phys. 1999. PMID: 10587234
-
Model 3500 125I brachytherapy source dosimetric characterization.Appl Radiat Isot. 2002 Apr;56(4):581-7. doi: 10.1016/s0969-8043(01)00254-8. Appl Radiat Isot. 2002. PMID: 11999156
-
Evaluation of a new brachytherapy iodine-125 source by AAPM TG43 formalism.Med Phys. 1998 Nov;25(11):2190-6. doi: 10.1118/1.598416. Med Phys. 1998. PMID: 9829244
-
Recommendations of the American Association of Physicists in Medicine regarding the impact of implementing the 2004 task group 43 report on dose specification for 103Pd and 125I interstitial brachytherapy.Med Phys. 2005 May;32(5):1424-39. doi: 10.1118/1.1884925. Med Phys. 2005. PMID: 15984693 Review.
-
Evaluation of a Proposed Biodegradable 188Re Source for Brachytherapy Application: A Review of Dosimetric Parameters.Medicine (Baltimore). 2015 Jul;94(28):e1098. doi: 10.1097/MD.0000000000001098. Medicine (Baltimore). 2015. PMID: 26181543 Free PMC article. Review.
Cited by
-
A review of brachytherapy physical phantoms developed over the last 20 years: clinical purpose and future requirements.J Contemp Brachytherapy. 2021 Feb;13(1):101-115. doi: 10.5114/jcb.2021.103593. Epub 2021 Feb 18. J Contemp Brachytherapy. 2021. PMID: 34025743 Free PMC article. Review.
-
Evaluation of an automated seed loader for seed calibration in prostate brachytherapy.J Appl Clin Med Phys. 2006 Winter;7(1):115-25. doi: 10.1120/jacmp.v7i1.2114. Epub 2006 Feb 15. J Appl Clin Med Phys. 2006. PMID: 16518323 Free PMC article.
-
Dosimetric parameters of three new solid core I-125 brachytherapy sources.J Appl Clin Med Phys. 2002 Spring;3(2):119-34. doi: 10.1120/jacmp.v3i2.2576. J Appl Clin Med Phys. 2002. PMID: 11958652 Free PMC article.
-
Clinical investigations on the spinal osteoblastic metastasis treated by combination of percutaneous vertebroplasty and (125)I seeds implantation versus radiotherapy.Cancer Biother Radiopharm. 2013 Feb;28(1):58-64. doi: 10.1089/cbr.2012.1204. Epub 2012 Sep 25. Cancer Biother Radiopharm. 2013. PMID: 23009581 Free PMC article. Clinical Trial.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources